On Thursday, Radius Health Inc (NASDAQ:RDUS)’s shares inclined 0.89% to $76.08.
Radius Health, Inc. (RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis in addition to other serious endocrine-mediated diseases, counting hormone responsive breast cancer, declared recently that it will present new data from multiple studies of abaloparatide in women with postmenopausal osteoporosis at the American Society for Bone and Mineral Research (ASBMR) 2015 Annual Meeting, October 9-12, 2015, at the Washington State Convention Center in Seattle, Washington, USA.
The company will be presenting a responder analysis of the effects of abaloparatide and teriparatide on bone mineral density in postmenopausal women with osteoporosis, the effects of abaloparatide on major osteoporotic fracture incidence in addition to pharmacokinetic data from the transdermal patch optimization program. Abstracts summarizing the abaloparatide data are published on the ASBMR website and are accessible to conference registrants and ASBMR members at: http://www.asbmr.org/ASBMR-abstracts.
Radius Health, Inc., a biopharmaceutical company, focuses on developing therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the United States. The company’s lead product comprises abaloparatide SC (BA058), a novel synthetic peptide analog of parathyroid hormone-related protein that is in Phase III clinical development for use in the reduction of fractures in postmenopausal osteoporosis; and Abaloparatide-TD, a line extension of abaloparatide-SC in the form of a transdermal patch that has accomplished Phase II clinical trial, which is used to enhance bone mineral density.
Colfax Corp (NYSE:CFX)’s shares dropped -1.56% to $41.02.
Colfax Corporation (CFX), a leading global manufacturer of gas- and fluid-handling and fabrication technology products and services, declared its financial results for the second quarter ended June 26, 2015.
For the second quarter of 2015, net income was $53.1 million, or $0.42 per dilutive share. Adjusted net income (as defined below) was $63.0 million, or $0.50 per share, contrast to $59.6 million for the second quarter of 2014, or $0.48 per share.
Net sales were $1,025.4 million in the second quarter, a decrease of 14.5% from the preceding year. Net sales reduced 4.5% organically contrast to the second quarter of 2014. Second quarter operating income was $96.6 million, with adjusted operating income (as defined below) of $105.4 million. Adjusted operating income margin (as defined below) was 10.3% in the second quarter, an enhance of 120 basis points from the preceding year.
Second quarter gas- and fluid-handling orders reduced by 15.4% to $502.3 million contrast to orders of $593.8 million for the second quarter of 2014, an organic order decrease of 4.7%. Gas- and fluid-handling finished the period with backlog of $1,364.4 million.
Colfax Corporation, an industrial manufacturing and engineering company, provides gas-and fluid-handling, and fabrication technology products and services to commercial and governmental customers worldwide. The company operates in two segments, Gas and Fluid Handling, and Fabrication Technology.
At the end of Thursday’s trade, Abraxas Petroleum Corp. (NASDAQ:AXAS)‘s shares surged 0.51% to $1.97.
Abraxas Petroleum Corporation (AXAS) will host its second quarter 2015 earnings conference call on Thursday, August 6, 2015 at 10 AM Central Time (11 AM Eastern Time). Abraxas plans to declare second quarter 2015 operating and financial results preceding to the call.
Abraxas Petroleum Corporation, an independent energy company, engages in the acquisition, exploitation, development, and production of oil and gas properties in the United States. The company operates oil and gas assets in the Rocky Mountain, Permian Basin, and onshore Gulf Coast regions.
Mead Johnson Nutrition CO (NYSE:MJN), ended its Thursday’s trading session with 2.47% gain, and closed at $91.17.
Mead Johnson Nutrition CO (MJN) declared that it is revising full-year 2015 financial guidance based on preliminary second quarter sales results. Results are preliminary at this time as the Company has not yet accomplished its quarter close processes. Final Q2 results will be declared on July 23, 2015.
- Preliminary second quarter constant dollar sales(1) were 3% below the preceding year quarter. Counting the impact of foreign currency, preliminary stated sales were 7% below the preceding year quarter.
- Strong sales of the recently launched imported products to China were insufficient to fully offset declines in the China based manufactured products. Hong Kong cross-border sales stabilized, but were below preceding year levels.
- Preliminary year-to-date sales were in-line with the preceding year on a constant-dollar basis and 4% lower on a stated basis.
- Slowing emerging market growth and dairy costs approaching five-year lows drove competitive promotional price discounting across several MJN markets in Latin America and Asia, most notably in China.
Mead Johnson Nutrition Company manufactures, distributes, and sells infant formulas, children’s nutrition, and other nutritional products. It offers routine infant formula products as a breast milk substitute for healthy infants for the use as the infant’s source of nutrition, in addition to a supplement to breastfeeding under the Enfamil Premium, Enfapro Premium, Enfamil A+, and Enfalac A+ names; and solutions products to address common feeding tolerance problems, counting spit-up, fussiness, gas, and lactose intolerance under the Enfamil Gentlease and Enfamil A.R names.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
